# US 11,999,805 B1 · Peptide inhibitors of CRISPR-Cas9 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,999,805 B1 - Document ID: US11999805B1 - Status: Granted - Kind: B1 - Application number: 16/867,698 - Filed: 2020-05-06 - Granted: 2024-06-04 - Earliest claimed: 2020-05-06 - Assignees: National Technology & Engineering Solutions of Sandia, LLC - Applicants: National Technology & Engineering Solutions of Sandia, LLC - Inventors: Brooke Nicole Harmon; Yooli Kim Light; Mary Bao Tran-Gyamfi; Joseph S. Schoeniger; Edwin A. Saada; Kenneth L. Sale - Web page: https://patentgrep.com/patent/US11999805B1 ## CPC - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases} - C07K 7/06: having 5 to 11 amino acids - C07K 14/001: {by chemical synthesis} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR] - C12N 2310/3513: Protein; Peptide - C12N 2310/3519: Fusion with another nucleic acid - C12Y 301/00: Hydrolases acting on ester bonds (3.1) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Y: ENZYMES ## Abstract Specific and broad-spectrum inhibitory peptides to CRISPR Cas9 variants (SpyCas9, SauCas9, and CjeCas9) are disclosed. A method of making and using these peptides with therapeutic CRISPR Cas9 (to improve desired targeting) or against harmful CRISPR Cas9 components (already active in a patient) is also disclosed. The peptides combined with a delivery system is also disclosed. ## Claims ### Claim 1 An agent selected from the group consisting of: an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1, 3-10, and 12-28 and combinations thereof; wherein the sequence identity is calculated over a full length of the amino acid sequence. ### Claim 2 (depends on 1) The agent of claim 1, wherein the amino acid sequence is identical to any of SEQ ID NOs: 1, 3-10, and 12-28. ### Claim 3 (depends on 1) The agent of claim 1, comprising a combination of two or more of the amino acid sequences having at least 90% sequence identity to any one of SEQ ID NOs: 1, 3-10, and 12-28. ### Claim 4 (depends on 1) The agent of claim 1, wherein the agent is a peptide selected from the peptides represented by SEQ ID NOs: 6, 13, and 17 and combinations thereof. ### Claim 5 A composition comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1, 3-10, and 12-28; and a pharmaceutically acceptable excipient; wherein the sequence identity is calculated over a full length of the amino acid sequence. ### Claim 6 (depends on 5) The composition of claim 5, wherein the composition is formulated for oral delivery. ### Claim 7 (depends on 5) The composition of claim 5, further comprising a CRISPR Cas9 agent. ### Claim 8 (depends on 7) The composition of claim 7, wherein the CRISPR Cas9 agent is a SpyCas9, SauCas9, or CjeCas9 variant. ### Claim 9 (depends on 5) The composition of claim 5, wherein the amino acid sequence is a peptide selected from the peptides represented by SEQ ID NOs: 6, 13, and 17 and combinations thereof. ### Claim 10 (depends on 5) The composition of claim 5, wherein the pharmaceutically acceptable excipient is a lipid-coated nanoparticle. ### Claim 11 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 6. ### Claim 12 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 13. ### Claim 13 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 17. ### Claim 14 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 5. ### Claim 15 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 7. ### Claim 16 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 16. ### Claim 17 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 22. ### Claim 18 (depends on 1) The agent of claim 1, wherein the agent is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 23.